 | | Vol. 14.17 – 12 May, 2023 |
| |
|
|
| Researchers sought in vivo genetic evidence for, and mechanistic understanding of, the role of B7 homolog 3 protein (B7-H3) in PTEN/TP53-deficient prostate cancer.
[Science Translational Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that atypical ubiquitination of androgen receptor mediated by an E3 ubiquitin ligase TRAF4 played an important role in castration-resistant prostate cancer development.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| The authors explored the mechanisms and potential combinatorial approaches with Cyst(e)inase for treatment of prostate cancer.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Investigators reported that NR3C1, the gene encoding glucocorticoid receptor, was a novel sex determining region Y-box 2 (SOX2) target in prostate cancer, positively regulating its expression.
[Cancer Letters] |
|
|
|
| The authors reported that silencing of transglutaminase-2 expression by CRISPR-Cas9 was associated with upregulation of androgen receptor transcription in prostate cancer cell lines.
[Cell Death & Disease] |
|
|
|
| Researchers showed that although Wnt was essential for prostate epithelial basal stem cell multipotency, ectopic Wnt activity promoted basal cell over-proliferation and squamous phenotypes, which were counteracted by elevated levels of androgen.
[Stem Cell Reports] |
|
|
|
| Investigators examined the expression of B7-H3 in prostate cancer tissues and cells and developed a second-generation chimeric antigen receptor (CAR) that specifically targeted B7-H3 and CD28 as costimulatory receptor to explore its tumoricidal potential against prostate cancer in vitro and in vivo.
[Cell Death Discovery] |
|
|
|
| Scientists investigated underlying mechanism of jumonji domain 2A (JMJD2A) in regulating cytoskeleton remodeling in castration-resistant prostate cancer resistant to docetaxel.
[BMC Cancer] |
|
|
|
| Researchers explored whether the FFA C8:0 could promote the progression of prostate cancer by up-regulating Krüppel-like factor 7.
[BMC Cancer] |
|
|
|
|
| Scientists review a comprehensive catalogue of single-cell omics studies and provide a more thorough understanding of the diagnosis and treatment of prostate cancer.
[Cellular & Molecular Biology Letters] |
|
|
|
| Investigators discuss new roles for androgen receptors (ARs) in other cancer types as well as their potential for treatment with AR-targeted agents.
[Endocrinology] |
|
|
|
|
| INmune Bio, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic castration-resistant prostate cancer.
[INmune Bio, Inc.] |
|
|
|
|
| June 2 – 6, 2023
Chicago, Illinois, United States |
|
|
|
|
|
| | Pfizer – New York, New York, United States |
|
|
|
| | The Brady Urological Institute – Baltimore, Maryland, United States |
|
|
|
| | Case Western Reserve University – Cleveland, Ohio, United States |
|
|
|
| | Harvard T.H. Chan School of Public Health – Boston, Massachusetts, United States |
|
|
|
| | University of Miami Desai Sethi Urology Institute – Miami, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
